Experimental cancer drug INCB062079 tested in early trial
NCT ID NCT03144661
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB062079
What this could lead to
If it works, this could point toward a treatment for certain advanced liver and other cancers with specific genetic changes.
What could go wrong
This is a very early, small Phase 1 trial that was terminated, so results are limited. The drug may not be effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Institut Jules Bordet
Brussels, 1000, Belgium
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University Hospital (UZ) Leuven
Leuven, 3000, Belgium
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of Toledo Medical Center
Toledo, Ohio, 43614, United States